Dexcom Gains FDA Clearance for G7 15-Day CGM and Smart Basal, Joins TEMPO Pilot Program

September 6, 2026

Simply Wall St USA

Overview

Dexcom has secured FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring (CGM) system, extending wear time to 15.5 days for all types of adult diabetes patients. Simultaneously, Dexcom Smart Basal, an integrated basal insulin optimization tool for adults with Type 2 diabetes using glargine U-100, also received FDA approval. These advancements enhance patient convenience and diabetes management, further supported by Dexcom’s selection as the first participant in the FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program.

In Depth

Key Findings

Dexcom has successfully obtained FDA clearance for its “Dexcom G7 15-Day” continuous glucose monitoring (CGM) system, an enhancement to its flagship Dexcom G7 product line. This approval extends the wear time for adults (18 years and older) with all types of diabetes to a maximum of 15.5 days, including a 12-hour grace period, significantly improving user convenience. Concurrently, “Dexcom Smart Basal,” an insulin dosing optimization tool for adults with Type 2 diabetes on glargine U-100 basal insulin therapy, also received FDA approval.

Technical / Clinical Details

The Dexcom G7 15-Day system provides real-time glucose data through a compact, wearable sensor. The extended wear period, including a 12-hour grace window, reduces the frequency of sensor changes, thereby lessening the burden on patients and potentially improving adherence. Dexcom Smart Basal is a software-based tool specifically designed for Type 2 diabetic adults utilizing long-acting insulins such as glargine U-100. It leverages data from the Dexcom G7 CGM to optimize basal insulin dosage, aiming to improve glycemic control. Clinical evidence consistently shows that CGM use contributes to significant reductions in HbA1c and increases time-in-range, with Smart Basal designed to facilitate data-driven treatment decisions.

Background & Context

Continuous Glucose Monitoring technology has profoundly transformed diabetes management, enhancing patient quality of life. Longer wear times directly contribute to increased patient convenience and improved treatment adherence. Furthermore, insulin therapy for Type 2 diabetes patients can be complex, and optimizing basal insulin is crucial for reducing hypoglycemia risk and achieving good glycemic control. In addition to these new product clearances, Dexcom has been selected as the first participant in the FDA’s Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program. This program aims to evaluate the impact of digital health technologies on patient outcomes and streamline regulatory pathways, highlighting Dexcom’s commitment to innovation and its potential contribution to the broader healthcare ecosystem.

Strategic Significance & Outlook

The market introduction of the Dexcom G7 15-Day and Smart Basal systems is expected to solidify Dexcom’s leadership in the diabetes technology market. The longer wear duration should boost patient adoption and could lead to cost savings across healthcare systems. Smart Basal such as insulin dosing optimization tool is particularly beneficial for Type 2 diabetes patients initiating insulin therapy, supporting safer and more effective treatment. Participation in the TEMPO program represents a critical opportunity for Dexcom to deepen its collaboration with the FDA in future digital health product development, promising more rapid technology adoption and enhanced value delivery to patients.

Source: https://simplywall.st/stocks/us/healthcare/nasdaq-dxcm/dexcom

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.